Deborah M. Stephens
Professor
Department of Hematology
Huntsman Cancer Institute
United States of America
Biography
Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with lymphoma and chronic lymphocytic leukemia (CLL). Her primary research interest is developing new targeted therapies for patients with lymphoma and CLL. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Her research has been widely published in influential journals such as the New England Journal of Medicine and the Journal of Clinical Oncology. On a national level, she is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is the Physician Leader of the SWOG CLL Working Group Committee, which is a group of CLL experts from academic centers around the country who plan and implement national clinical trials to improve the standard-of-care for CLL patients across the country. The sum of Dr. Stephens's experiences demonstrate her deep commitment to improve the care of patients with CLL and lymphoma.
Research Interest
Internal Medicine Hematology
Publications
-
Luo C, Deng Z, Li L, Clayton F, Chen AL, Wei R, Miles R, Stephens DM, Glenn M, Wang X, Jensen PE, Chen X (2016). Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. Oncotarget, 7(11), 12806-22.
-
Rogers KA, Salem G, Stephens DM, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Huang Y, Ruppert AS, Jones JA (2017). A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter’s transformation of chronic lymphocytic leukemia. 2017 Feb. Submitted for publication. Blood.
-
Juster-Switlyk K, Smith G, Kovacsovics T, Stephens DM, Glenn M, Kolb N (2017). MTHFR C667T polymorphism is associated with methotrexate-induced myelopathy risk. Neurology, 7(88 6), 603-604.